Cargando…

Serum IL-17, IL-23, and TGF-β Levels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls

Type 1 diabetes is recognized as an autoimmune inflammatory disease and low grade inflammation is also observed in type 2 diabetic patients. Interleukin 17 (IL-17) is a new player in inflammation. Th17 cells, as the main source of IL-17, require transforming growth factor β (TGF-β) and interleukin 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Roohi, Azam, Tabrizi, Mina, Abbasi, Farzaneh, Ataie-Jafari, Asal, Nikbin, Behrouz, Larijani, Bagher, Qorbani, Mostafa, Meysamie, Alipasha, Asgarian-Omran, Hossein, Nikmanesh, Bahram, Bajouri, Arezou, Shafiey, Novin, Maleki, Akram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065742/
https://www.ncbi.nlm.nih.gov/pubmed/24995325
http://dx.doi.org/10.1155/2014/718946
_version_ 1782322136041390080
author Roohi, Azam
Tabrizi, Mina
Abbasi, Farzaneh
Ataie-Jafari, Asal
Nikbin, Behrouz
Larijani, Bagher
Qorbani, Mostafa
Meysamie, Alipasha
Asgarian-Omran, Hossein
Nikmanesh, Bahram
Bajouri, Arezou
Shafiey, Novin
Maleki, Akram
author_facet Roohi, Azam
Tabrizi, Mina
Abbasi, Farzaneh
Ataie-Jafari, Asal
Nikbin, Behrouz
Larijani, Bagher
Qorbani, Mostafa
Meysamie, Alipasha
Asgarian-Omran, Hossein
Nikmanesh, Bahram
Bajouri, Arezou
Shafiey, Novin
Maleki, Akram
author_sort Roohi, Azam
collection PubMed
description Type 1 diabetes is recognized as an autoimmune inflammatory disease and low grade inflammation is also observed in type 2 diabetic patients. Interleukin 17 (IL-17) is a new player in inflammation. Th17 cells, as the main source of IL-17, require transforming growth factor β (TGF-β) and interleukin 23 (IL-23). The aim of this study was to investigate serum IL-17, IL-23 and TGF-β levels in diabetic patients and controls. In this case-control study, serum levels of IL-17, IL-23, and TGF-β were measured in 24 type 1 diabetic patients and 30 healthy controls using the ELISA method. Simultaneously, the same methodology was used to compare serum concentration of these three cytokines in 38 type 2 diabetic patients and 40 healthy controls. There was no significant difference between serum levels of IL-17 and IL-23 cytokines between cases and controls. However, TGF-β was significantly lower in type 1 diabetic patients (P < 0.001). Serum IL-17 and IL-23 levels demonstrate no association with type 1 and type 2 diabetes, but, in line with previous studies, TGF-β levels were lower in type 1 diabetic patients.
format Online
Article
Text
id pubmed-4065742
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40657422014-07-03 Serum IL-17, IL-23, and TGF-β Levels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls Roohi, Azam Tabrizi, Mina Abbasi, Farzaneh Ataie-Jafari, Asal Nikbin, Behrouz Larijani, Bagher Qorbani, Mostafa Meysamie, Alipasha Asgarian-Omran, Hossein Nikmanesh, Bahram Bajouri, Arezou Shafiey, Novin Maleki, Akram Biomed Res Int Research Article Type 1 diabetes is recognized as an autoimmune inflammatory disease and low grade inflammation is also observed in type 2 diabetic patients. Interleukin 17 (IL-17) is a new player in inflammation. Th17 cells, as the main source of IL-17, require transforming growth factor β (TGF-β) and interleukin 23 (IL-23). The aim of this study was to investigate serum IL-17, IL-23 and TGF-β levels in diabetic patients and controls. In this case-control study, serum levels of IL-17, IL-23, and TGF-β were measured in 24 type 1 diabetic patients and 30 healthy controls using the ELISA method. Simultaneously, the same methodology was used to compare serum concentration of these three cytokines in 38 type 2 diabetic patients and 40 healthy controls. There was no significant difference between serum levels of IL-17 and IL-23 cytokines between cases and controls. However, TGF-β was significantly lower in type 1 diabetic patients (P < 0.001). Serum IL-17 and IL-23 levels demonstrate no association with type 1 and type 2 diabetes, but, in line with previous studies, TGF-β levels were lower in type 1 diabetic patients. Hindawi Publishing Corporation 2014 2014-06-04 /pmc/articles/PMC4065742/ /pubmed/24995325 http://dx.doi.org/10.1155/2014/718946 Text en Copyright © 2014 Azam Roohi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Roohi, Azam
Tabrizi, Mina
Abbasi, Farzaneh
Ataie-Jafari, Asal
Nikbin, Behrouz
Larijani, Bagher
Qorbani, Mostafa
Meysamie, Alipasha
Asgarian-Omran, Hossein
Nikmanesh, Bahram
Bajouri, Arezou
Shafiey, Novin
Maleki, Akram
Serum IL-17, IL-23, and TGF-β Levels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls
title Serum IL-17, IL-23, and TGF-β Levels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls
title_full Serum IL-17, IL-23, and TGF-β Levels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls
title_fullStr Serum IL-17, IL-23, and TGF-β Levels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls
title_full_unstemmed Serum IL-17, IL-23, and TGF-β Levels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls
title_short Serum IL-17, IL-23, and TGF-β Levels in Type 1 and Type 2 Diabetic Patients and Age-Matched Healthy Controls
title_sort serum il-17, il-23, and tgf-β levels in type 1 and type 2 diabetic patients and age-matched healthy controls
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065742/
https://www.ncbi.nlm.nih.gov/pubmed/24995325
http://dx.doi.org/10.1155/2014/718946
work_keys_str_mv AT roohiazam serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT tabrizimina serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT abbasifarzaneh serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT ataiejafariasal serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT nikbinbehrouz serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT larijanibagher serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT qorbanimostafa serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT meysamiealipasha serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT asgarianomranhossein serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT nikmaneshbahram serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT bajouriarezou serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT shafieynovin serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols
AT malekiakram serumil17il23andtgfblevelsintype1andtype2diabeticpatientsandagematchedhealthycontrols